Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8532388 | Journal of Ethnopharmacology | 2018 | 30 Pages |
Abstract
L-Dopa (LD) in Mucuna pruriens (L.) DC gets converted into dopamine (DA) by DOPA decarboxylase (DDC) enzyme. DA binds to the DA receptor subtype 2 (DRD2), which by coupling with inhibitory heterotrimeric G proteins (Gi and Go), results in the inhibition of production and secretion of prolactin (PRL). Unavailable to prolactin receptor (PRLR), PRL is unable to induce their dimerization leading to blockade of series of events including, PRLR phosphorylation, activation of JAK2 and subsequent activation of STAT5A protein which further activates promoter of Cyclin D1 and would otherwise lead to the increased cellular proliferation of breast cancer cells. Further, MP when combined with Cisplatin (Pt) inhibits otherwise activated PRL-mediated JAK2 pathway, reduces glutathione-s-transferase (GST) activity and allow Cisplatin to enter into the nucleus and form abduct with DNA, increasing the efficacy of cisplatin as compared to its administration alone in breast cancer cells.372
Keywords
STAT5APRLRJanus Kinase 2DRD2GSTPRLGPCRsJAK23-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromideG protein-coupled receptorsl-DOPAMTTanalysis of varianceANOVADopamineBreast cancercisplatinlevodopaMucuna pruriensHyperprolactinemiaProlactinChemoresistanceglutathione S-transferasedopamine receptor D2prolactin receptor
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Sonam Sinha, Sonal Sharma, Jaykant Vora, Heta Shah, Anshu Srivastava, Neeta Shrivastava,